Molecular pharmacology in complement‐mediated hemolytic disorders

伊库利珠单抗 冷凝集素病 阵发性夜间血红蛋白尿 自身免疫性溶血性贫血 美罗华 医学 非典型溶血尿毒综合征 补体系统 免疫学 溶血性贫血 凝集素途径 替代补体途径 抗体
作者
Marta Bortolotti,Wilma Barcellini,Bruno Fattizzo
出处
期刊:European Journal of Haematology [Wiley]
卷期号:111 (3): 326-336 被引量:19
标识
DOI:10.1111/ejh.14026
摘要

Abstract In the last decade, a deeper understanding of the pathogenesis of complement mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD), warm type autoimmune hemolytic anemia (AIHA) with complement activation (wAIHA), and atypical hemolytic uremic syndrome (aHUS), paved the way to the therapeutic shift from purely supportive approaches to complement‐targeted therapies. This resulted in a significant improvement in disease management, survival, and quality of life. In this review, we will provide a snapshot of novel therapies for complement‐mediated hemolytic anemias with a focus on those ready to use in clinical practice. C5 inhibitors eculizumab and the long‐acting ravulizumab, are the established gold standard for untreated PNH patients, whilst the C3 inhibitor pegcetacoplan should be considered for suboptimal responders to anti‐C5 drugs. Several additional compounds targeting the complement cascade at different levels (other C5 inhibitors, factor B and D inhibitors) are under active investigation with promising results. In CAD, immunosuppression with rituximab remains the first‐line. However, recently FDA and EMA approved the anti‐C1s monoclonal antibody, sutimlimab, that showed dramatic responses and whose regulatory approval is soon awaited in many countries. Other drugs under investigation in AIHA include the C3 inhibitor pegcetacoplan, and the anti‐C1q ANX005 for warm AIHA with complement activation. Finally, aHUS is an indication for complement inhibitors. Eculizumab and ravulizumab have been approved, whilst other C5 inhibitors, and novel lectin pathway inhibitors are under active investigation in this disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
2秒前
hehe_733发布了新的文献求助10
4秒前
我是老大的应助被科研通管家采纳,获得10
4秒前
张伟的应助被科研通管家采纳,获得10
4秒前
元吉的应助被科研通管家采纳,获得10
4秒前
ding的应助被科研通管家采纳,获得10
4秒前
小蘑菇的应助被zzz采纳,获得10
4秒前
李健的应助被科研通管家采纳,获得10
4秒前
5秒前
传奇3的应助被科研通管家采纳,获得10
5秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
5秒前
蜡笔大新眼子完成签到,获得积分10
5秒前
打打的应助被科研通管家采纳,获得10
5秒前
5秒前
脑洞疼的应助被科研通管家采纳,获得10
5秒前
李爱国的应助被科研通管家采纳,获得30
5秒前
5秒前
5秒前
哇啦的应助被科研通管家采纳,获得10
6秒前
无极微光的应助被科研通管家采纳,获得20
6秒前
6秒前
完美世界的应助被科研通管家采纳,获得10
6秒前
fantasy的应助被科研通管家采纳,获得10
6秒前
好好好发布了新的文献求助10
6秒前
情怀的应助被Viv采纳,获得10
7秒前
7秒前
小白完成签到,获得积分10
8秒前
CAOHOU的应助被刘刘采纳,获得10
9秒前
369ninja的应助被刘刘采纳,获得10
9秒前
勤奋仙人掌的应助被刘刘采纳,获得10
9秒前
勤奋仙人掌的应助被刘刘采纳,获得10
9秒前
勤奋仙人掌的应助被刘刘采纳,获得10
9秒前
Hello的应助被刘刘采纳,获得10
9秒前
9秒前
WUT完成签到,获得积分0
10秒前
一颗药顽完成签到,获得积分10
11秒前
11秒前
好的好的的应助被WYL采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191198
求助须知:如何正确求助?哪些是违规求助? 9578129
关于积分的说明 21856860
捐赠科研通 7790454
什么是DOI,文献DOI怎么找? 3436543
关于科研通互助平台的介绍 2560339
邀请新用户注册赠送积分活动 2483298